INTRODUCTION: Precision medicine (PM) represents a tailored management based on specific patient biological and medical characteristics, at a highly detailed level, including disease screening, monitoring relapse and/or recurrence, selection and/or prediction of effective drug and/or surgical treatment. PM may be applied to Phlebology and Wound Care area and the aim of this review is to analyze the most updated information on this topic. EVIDENCE ACQUISITION: The following key words were used to search the literature: "precision medicine and phlebology/venous disease," "precision medicine and wound care," "biomarkers and phlebology/venous disease," "biomarkers and wound care." All of those studies which did not fit the query or which reported insufficient data were excluded. EVIDENCE SYNTHESIS: Of the 6845 records yielded by the search, after duplicate removing and after excluded records in title and abstract, 250 articles were left, which matched fulfilled the inclusion criteria. After reading the articles in full text, 203 were excluded because: 1) not responding properly to our research questions; 2) insufficient data; thefinal set included 47 articles. CONCLUSIONS: In the context of phlebology and wound care, PM, through the use of measurable biomarkers coming from omics analysis, may be used in selecting the appropriate treatment, in evaluating response to treatment, and in monitoring recurrences. Thus, a tailored medical approach to patients with vein and chronic wound disease may be useful in order lower the high incidence of important clinical conditions that have great socio-economic impact on the general population.

Biomarkers for precision medicine in phlebology and wound care. A systematic review / Serra, R.; Ielapi, N.; Barbetta, A.; Buffone, G.; Bevacqua, E.; Andreucci, M.; De Franciscis, S.; Gasbarro, V.. - In: ACTA PHLEBOLOGICA. - ISSN 1593-232X. - 18:2(2017), pp. 52-56. [10.23736/S1593-232X.17.00394-0]

Biomarkers for precision medicine in phlebology and wound care. A systematic review

Ielapi N.;
2017

Abstract

INTRODUCTION: Precision medicine (PM) represents a tailored management based on specific patient biological and medical characteristics, at a highly detailed level, including disease screening, monitoring relapse and/or recurrence, selection and/or prediction of effective drug and/or surgical treatment. PM may be applied to Phlebology and Wound Care area and the aim of this review is to analyze the most updated information on this topic. EVIDENCE ACQUISITION: The following key words were used to search the literature: "precision medicine and phlebology/venous disease," "precision medicine and wound care," "biomarkers and phlebology/venous disease," "biomarkers and wound care." All of those studies which did not fit the query or which reported insufficient data were excluded. EVIDENCE SYNTHESIS: Of the 6845 records yielded by the search, after duplicate removing and after excluded records in title and abstract, 250 articles were left, which matched fulfilled the inclusion criteria. After reading the articles in full text, 203 were excluded because: 1) not responding properly to our research questions; 2) insufficient data; thefinal set included 47 articles. CONCLUSIONS: In the context of phlebology and wound care, PM, through the use of measurable biomarkers coming from omics analysis, may be used in selecting the appropriate treatment, in evaluating response to treatment, and in monitoring recurrences. Thus, a tailored medical approach to patients with vein and chronic wound disease may be useful in order lower the high incidence of important clinical conditions that have great socio-economic impact on the general population.
2017
evidence-based medicine; phlebology; precision medicine - biomarkers; wounds and injuries
01 Pubblicazione su rivista::01g Articolo di rassegna (Review)
Biomarkers for precision medicine in phlebology and wound care. A systematic review / Serra, R.; Ielapi, N.; Barbetta, A.; Buffone, G.; Bevacqua, E.; Andreucci, M.; De Franciscis, S.; Gasbarro, V.. - In: ACTA PHLEBOLOGICA. - ISSN 1593-232X. - 18:2(2017), pp. 52-56. [10.23736/S1593-232X.17.00394-0]
File allegati a questo prodotto
File Dimensione Formato  
Serra_Biomarkers_2017.pdf

solo gestori archivio

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 482.85 kB
Formato Adobe PDF
482.85 kB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1354167
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 12
  • ???jsp.display-item.citation.isi??? 11
social impact